comment
opinion
articl
fda
approv
drug
potenti
ebola
treatment
ref
statu
index
http
abstract
search
treatment
ebola
viru
multipl
screen
fda
drug
led
identif
sever
promis
activ
vitro
compound
origin
develop
antivir
test
mous
model
put
forward
opinion
vivo
drug
could
evalu
move
clinic
alreadi
fda
approv
mani
case
readili
avail
may
import
outbreak
futur
therapeut
avail
drug
mobil
app
http
molmatinfcomapproveddrugshtml
supplement
figur
amodiaquin
similar
approv
drug
mobil
app
http
molmatinfcomapproveddrugshtml
pubm
abstract
publish
full
text
trad
fisher
da
tambyah
pa
et
al
ebola
west
africa
lancet
infect
di
pubm
abstract
publish
full
text
madrid
pb
chopra
manger
id
et
al
systemat
screen
fdaapprov
drug
inhibitor
biolog
threat
agent
plo
one
pubm
abstract
publish
full
text
free
full
text
de
wild
ah
jochman
posthuma
cc
et
al
screen
fdaapprov
compound
librari
identifi
four
smallmolecul
inhibitor
middl
east
respiratori
syndrom
coronaviru
replic
cell
cultur
antimicrob
agent
chemoth
pubm
abstract
publish
full
text
free
full
text
keyaert
e
li
vijgen
l
et
al
antivir
activ
chloroquin
human
coronaviru
infect
newborn
mice
antimicrob
agent
chemoth
pubm
abstract
publish
full
text
free
full
text
vincent
mj
bergeron
e
benjannet
et
al
chloroquin
potent
inhibitor
sar
coronaviru
infect
spread
virol
j
pubm
abstract
publish
full
text
free
full
text
boonyasuppayakorn
reichert
ed
manzano
et
al
amodiaquin
antimalari
drug
inhibit
dengu
viru
type
replic
infect
antivir
re
pubm
abstract
publish
full
text
johansen
lm
brannan
jm
delo
se
et
al
fdaapprov
select
estrogen
receptor
modul
inhibit
ebola
viru
infect
sci
transl
med
pubm
abstract
publish
full
text
free
full
text
gehr
g
rohrmann
k
atenchong
n
et
al
clinic
approv
drug
amiodaron
dronedaron
verapamil
inhibit
filoviru
cell
entri
j
antimicrob
chemoth
pubm
abstract
publish
full
text
ekin
freundlich
js
coffe
et
al
common
featur
pharmacophor
fdaapprov
drug
inhibit
ebola
viru
ref
statu
index
http
pubm
abstract
publish
full
text
free
full
text
veljkov
v
loiseau
pm
figader
b
et
al
virtual
screen
repurpos
approv
experiment
drug
candid
inhibitor
ebola
viru
infect
ref
statu
index
http
publish
full
text
kouznetsova
j
sun
w
c
et
al
identif
compound
block
ebola
viruslik
particl
entri
via
repurpos
screen
approv
drug
emerg
microb
infect
publish
full
text
long
j
wright
e
molesti
e
et
al
antivir
therapi
ebola
emerg
viral
diseas
use
exist
medicin
block
viru
entri
ref
statu
await
peer
review
http
publish
full
text
litterman
n
lipinski
c
ekin
et
al
small
molecul
antivir
activ
ebola
viru
ref
statu
index
http
publish
full
text
picazo
e
giordanetto
f
small
molecul
inhibitor
ebola
viru
infect
drug
discov
today
pubm
abstract
publish
full
text
yan
h
zhong
g
xu
g
et
al
sodium
taurochol
cotransport
polypeptid
function
receptor
human
hepat
b
viru
elif
page
last
updat
mar
pubm
abstract
publish
full
text
free
full
text
dong
z
ekin
polli
je
et
al
quantit
ntcp
pharmacophor
lack
associ
dili
ntcp
inhibit
eur
j
pharm
sci
pubm
abstract
publish
full
text
fu
liu
j
chen
et
al
silico
analysi
experiment
valid
azelastin
hydrochlorid
target
sodium
taurochol
cotransport
polypeptid
ntcp
hbv
therapi
cell
prolif
pubm
abstract
publish
full
text
blatt
j
farag
corey
sj
et
al
expand
scope
drug
repurpos
pediatr
children
pharmaci
collabor
drug
discov
today
pubm
abstract
publish
full
text
dyall
j
coleman
cm
hart
bj
et
al
repurpos
clinic
develop
drug
treatment
middl
east
respiratori
syndrom
coronaviru
infect
antimicrob
agent
chemoth
pubm
abstract
publish
full
text
free
full
text
huang
r
southal
n
wang
et
al
ncgc
pharmaceut
collect
comprehens
resourc
clinic
approv
drug
enabl
repurpos
chemic
genom
sci
transl
med
pubm
abstract
publish
full
text
free
full
text
oprea
ti
mestr
j
drug
repurpos
far
beyond
new
target
old
drug
aap
j
pubm
abstract
publish
full
text
free
full
text
walsh
ct
fischbach
repurpos
librari
eukaryot
protein
kinas
inhibitor
antibiot
discoveri
proc
natl
acad
sci
u
pubm
abstract
publish
full
text
free
full
text
dudley
jt
deshpand
butt
aj
exploit
drugdiseas
relationship
comput
drug
reposit
brief
bioinform
pubm
abstract
publish
full
text
free
full
text
dudley
jt
sirota
shenoy
et
al
comput
reposit
anticonvuls
topiram
inflammatori
bowel
diseas
sci
transl
med
pubm
abstract
publish
full
text
free
full
text
ekin
william
aj
krasowski
md
et
al
silico
reposit
approv
drug
rare
neglect
diseas
drug
discov
today
pubm
abstract
publish
full
text
ekin
southan
c
coffe
find
small
molecul
next
ebola
ref
statu
await
peer
review
http
ebola
outbreak
continu
cost
spiral
perhap
consid
altern
treatment
close
hand
africa
complement
public
health
measur
use
date
two
independ
studi
fund
us
defens
threat
reduct
agenc
identifi
fda
approv
drug
worthi
evalu
work
seem
prescient
although
appear
follow
public
conclus
one
studi
antimalari
amodiaquin
chloroquin
figur
found
activ
use
vitro
cell
cultur
assay
vivo
mous
model
drug
cheap
gener
safe
like
readili
access
africa
compound
also
shown
rel
broad
activ
virus
vitro
vivo
anim
model
dengu
coronaviru
sar
etc
second
studi
suggest
select
estrogen
receptor
modul
serm
clomiphen
toremifen
figur
inhibitor
ebola
viru
latter
compound
like
access
west
indic
fda
emea
approv
drug
may
worth
test
includ
hormon
effect
serm
recent
work
europ
identifi
fda
drug
amiodaron
dronedaron
verapamil
figur
inhibit
filoviru
entri
plasma
level
attain
human
mechan
action
drug
unknown
although
use
comput
method
recent
shown
antimalari
serm
may
share
pharmacophor
featur
may
import
infer
potenti
common
target
target
knowledg
like
well
small
druglik
molecul
identifi
activ
ebola
viru
includ
fda
drug
deriv
report
assay
ncat
await
develop
vaccin
biolog
could
consid
assess
efficaci
antimalari
fda
approv
drug
either
treatment
prophylact
prevent
ebola
viru
spread
guarante
work
perhap
requir
adjust
dosag
may
last
resort
possibl
nonantivir
wide
use
africa
may
also
effect
ebola
anoth
exampl
nonantivir
fda
approv
drug
found
antivir
activ
hepat
viru
b
sodium
taurochol
cotransport
polypeptid
ntcp
identifi
receptor
screen
produc
drug
azelastin
pioglitazon
glyburid
irbesartan
ezetimib
inhibit
transport
may
provid
potenti
treatment
compound
azelastin
shown
possess
vitro
activ
hepat
viru
b
date
edit
manuscript
focu
simpl
approach
use
known
activ
propos
addit
fda
approv
compound
test
supplement
figur
includ
show
similar
search
molecul
figur
activ
ebola
viru
refer
recent
commentari
suggest
involv
physician
perspect
includ
address
review
comment
criteria
decis
select
process
aforement
screen
fda
approv
drug
ebola
viru
activ
far
comprehens
cover
known
approv
drug
current
use
age
drug
repurpos
vogu
facilit
comput
method
would
seem
valuabl
resourc
find
compound
activ
ebola
viru
exampl
recent
pharmacophor
develop
ebola
virtual
screen
could
use
comput
search
larger
dataset
fda
approv
drug
priorit
addit
compound
test
vitro
even
use
known
activ
figur
perform
simpl
similar
search
set
approv
drug
mobil
app
http
molmatinfcomapproveddrugshtml
could
priorit
compound
test
figur
figur
exampl
molecul
structur
similar
chloroquin
figur
includ
known
activ
like
amodiaquin
hydroxychloroquin
also
suggest
antimalari
primaquin
halofantrin
antihistamin
chlorpheniramin
molecul
similar
amodiaquin
includ
kinas
inhibitor
neratinib
gefitinib
kinas
inhibitor
suggest
activ
ebola
viru
may
readili
access
africa
compound
retriev
similar
includ
antimicrobi
pentamidin
figur
figur
figur
antiemet
trimethobenzamid
figur
figur
antihistamin
doxylamin
figur
certainli
sophist
exhaust
search
could
tri
decid
molecul
use
test
also
involv
physician
perspect
altern
treatment
may
also
found
studi
close
patient
may
contract
diseas
take
drug
anoth
chronic
diseas
whether
find
treatment
ebola
serendip
question
publish
studi
known
drug
might
point
us
right
direct
look
opportun
put
alreadi
avail
drug
like
alreadi
identifi
back
tabl
may
use
tool
frontlin
doctor
worthi
urgent
discuss
research
author
contribut
write
manuscript
neither
author
compet
interest
author
declar
grant
involv
support
work
compet
interest
disclos
opinion
articl
provid
interest
potenti
import
view
current
approv
drug
may
activ
ebola
viru
would
allow
rapid
entri
clinic
use
due
previou
approv
statu
concept
consist
previou
scientif
discuss
potenti
repurpos
drug
focu
ebola
viru
german
immedi
medic
crisi
need
effect
therapi
relat
ebola
infect
present
opinion
provid
high
level
overview
previous
publish
data
identifi
agent
potenti
efficaci
opinion
appropri
expand
concept
use
comput
approach
identifi
drug
potenti
activ
concept
studi
ebola
viru
expos
individu
contract
diseas
approach
identifi
drug
may
benefici
effect
good
although
fraught
difficulti
studi
may
attempt
field
condit
point
expand
author
encourag
give
addit
thought
provid
addit
opinion
regard
approach
taken
beyond
identif
drug
may
potenti
efficaci
ebola
outbreak
sinc
opinion
recommend
addit
screen
drug
potenti
efficaci
decis
made
select
specif
agent
evalu
clinic
use
criteria
deem
essenti
make
decis
select
process
use
criteria
deem
essenti
make
decis
select
process
critic
issu
sinc
limit
resourc
alway
limit
requir
decis
molecul
priorit
select
next
level
evalu
use
read
submiss
believ
appropri
level
expertis
confirm
accept
scientif
standard
howev
signific
reserv
outlin
compet
interest
disclos
author
respons
mar
collabor
chemistri
usa
thank
review
latest
version
compound
figur
known
ebola
viru
activ
vitro
vivo
use
start
point
similar
search
fda
approv
drug
mobil
app
type
approach
could
like
taken
softwar
would
suggest
sever
fda
approv
molecul
could
readili
test
may
access
africa
eg
addit
antimalari
antimicrobi
etc
unclear
test
date
type
approach
could
taken
larger
scale
may
also
point
import
tertiari
amin
compound
mechan
recent
opinion
http
discuss
use
physician
perspect
group
treatment
address
review
question
criteria
may
essenti
differ
take
approach
therapeut
ebola
idea
use
nonantivir
potenti
therapeut
broach
natur
extend
proposit
ebola
author
provid
good
summari
candid
agent
laboratori
evid
suggest
might
worth
tri
although
mechanist
explan
avail
one
mechan
common
effect
cell
membran
transport
pore
use
class
drug
would
also
larg
overcom
ethic
issu
pertain
experiment
drug
cours
practic
conduct
clinic
trial
would
challeng
might
appear
find
appropri
case
control
fact
mortal
seem
also
larg
determin
earli
access
support
measur
like
rehydrationthes
complic
abil
detect
outcom
differ
subject
rerepurpos
drug
note
also
nonebola
antivir
might
repurpos
ebola
eg
favipiravir
approv
influenza
countri
